Aro Biotherapeutics Stock

Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines.

Sign up today and learn more about Aro Biotherapeutics Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Aro Biotherapeutics Stock

Aro Biotherapeutics is focused on the development of a new protein drug platform called Centyrins, designed to achieve better efficacy and safety profiles for patients with cancer and other serious diseases. Centyrins are small, non-antibody protein scaffolds that can be expressed as multi-specifics with novel therapeutic mechanisms of action. Centyrins are also ideal for the targeted delivery of complex drug payloads, including nucleic acids.

Funding History

December 2018$13.0M
January 2021$88.0M
December 2022$24.0M


Co-founder and Chief Scientific Officer

Karyn O’Neil

Co-founder, President and Chief Executive Officer

Susan Dillon

Chief Business Officer & Head of Corporate Strategy

Derek Miller

Chief Administrative Officer (CAO)

Mark Laurenzi

Board Member

Bruce A. Peacock

Chief Technology Officer

Sukumar Sakamuri

Board Member

Liz McKee Anderson


Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: